

## Reimbursement Policy

### Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease

---

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

#### I. Policy Description

Chronic liver disease (CLD) refers to a wide range of liver pathologies that include inflammation (chronic hepatitis), liver cirrhosis, and hepatocellular carcinoma.

Hepatic fibrosis is associated with a cycle of extracellular matrix deposition and degradation. Biomarkers of extracellular matrix turnover are used to directly assess fibrosis and, theoretically, to monitor progression or regression.<sup>1</sup> These markers include several glycoproteins, members of the collagen family, collagenases and their inhibitors, and several cytokines involved in the fibrogenic process.<sup>1</sup> The markers may be utilized individually, as well as in panel combinations.<sup>2</sup>

#### II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- 1) For individuals with a chronic hepatitis B (HBV) or chronic hepatitis C (HCV) viral infection, FibroSURE® (i.e., HBV FibroSURE®, HCV FibroSURE®), ELFTM(ELFTM), **or** FibroTest® testing once every six months **MEETS COVERAGE CRITERIA.**
- 2) For individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) (including metabolic dysfunction-associated steatohepatitis [MASH]), **or** alcoholic hepatitis, or to rule out compensated advanced chronic liver disease (cACLD) for individuals with an elevated liver stiffness measurement, ELFTM(ELFTM) **or** FibroTest® testing once every six months **MEETS COVERAGE CRITERIA.**
- 3) For all situations, including for individuals with any of the conditions described above, the use of other multianalyte assays with algorithmic analysis (e.g., ASH FibroSURE®, LIVERFAST™, NASH FibroSURE®, OWLiver®) **DOES NOT MEET COVERAGE CRITERIA.**

## Reimbursement Policy

- 4) For individuals with liver disease not meeting the above criteria, the use of ELFT™(ELFTM), FibroTest®, HBV FibroSURE®, **and/or** HCV FibroSURE® **DOES NOT MEET COVERAGE CRITERIA.**

*The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.*

- 5) Except when included as a component of one of the multianalyte assays described above, the use of the following serum biomarkers in the diagnosis, prognosis, or monitoring of chronic liver disease **DOES NOT MEET COVERAGE CRITERIA:**
- a) Signal-induced proliferation-associated 1 like 1 (SIPA1L1)
  - b) microRNA (miRNA or miR) analysis, including but not limited to, the following:
    - i) microRNA-21 (miRNA-21 or miR-21)
    - ii) miRNA-29a (miR-29a)
    - iii) miRNA-122 (miR-122)
    - iv) miRNA-221 (miR-221)
    - v) miRNA-222 (miR-222)
  - c) Chitinase 3-like 1 (CHI3L1)
  - d) Hyaluronic acid
  - e) Type III procollagen (PCIII)
  - f) Type IV collagen
  - g) Laminin
  - h) Plasma caspase-generated cytokeratin-18
  - i) Micro-fibrillar associated glycoprotein 4 (MFAP4)

### III. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

## Reimbursement Policy

### Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

### IV. Applicable CPT/HCPCS Procedure Codes

| CPT   | Code Description                                                                                                                                                                                                                                                                                                                                                                                         |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 81517 | Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years                                                                        |
| 81599 | Unlisted multianalyte assay with algorithmic analysis                                                                                                                                                                                                                                                                                                                                                    |
| 84999 | Unlisted chemistry procedure                                                                                                                                                                                                                                                                                                                                                                             |
| 0002M | Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic steatohepatitis (ASH)<br>Proprietary test: ASH FibroSURE™<br>Laboratory/Manufacturer: BioPredictive S.A.S            |
| 0003M | Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH)<br>Proprietary test: NASH FibroSURE™<br>Laboratory/Manufacturer: BioPredictive S.A.S       |
| 0166U | Liver disease, 10 biochemical assays (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation<br>Proprietary test: LiverFASt™<br>Lab/Manufacturer: Fibronostics |
| 0344U | Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH                                                                                                                                                 |

## Reimbursement Policy

| CPT   | Code Description                                                                                                                                                                                                                                                   |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | Proprietary test: OWLiver®<br>Lab/Manufacturer: CIMA Sciences, LLC                                                                                                                                                                                                 |
| 0468U | Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis<br>Proprietary test: NASHnextTM (NIS4TM)<br>Lab/Manufacturer: Labcorp |

Current Procedural Terminology© American Medical Association. All Rights reserved.

*Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.*

### V. Evidence-based Scientific References

1. Valva P, Rios DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. *World journal of gastroenterology*. Jan 28 2016;22(4):1367-81. doi:10.3748/wjg.v22.i4.1367
2. Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. *Annals of translational medicine*. Feb 2017;5(3):40. doi:10.21037/atm.2017.01.28
3. EASL. Multinational liver societies announce new “Fatty” liver disease nomenclature that is affirmative and non-stigmatising. [https://easl.eu/news/new\\_fatty\\_liver\\_disease\\_nomenclature-2/](https://easl.eu/news/new_fatty_liver_disease_nomenclature-2/)
4. Friedman SL. Pathogenesis of hepatic fibrosis. Updated April 2, 2025. <https://www.uptodate.com/contents/pathogenesis-of-hepatic-fibrosis>
5. Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? *Frontiers in pharmacology*. 2016;7:159. doi:10.3389/fphar.2016.00159
6. Curry M, Afdhal N. Noninvasive assessment of hepatic fibrosis: Overview of serologic and radiographic tests. Updated March 13, 2025. <https://www.uptodate.com/contents/noninvasive-assessment-of-hepatic-fibrosis-overview-of-serologic-tests-and-imaging-examinations>
7. Bracht T, Molleken C, Ahrens M, et al. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. *Journal of translational medicine*. Jul 4 2016;14(1):201. doi:10.1186/s12967-016-0952-3
8. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. *Journal of hepatology*. Jan 2014;60(1):167-74. doi:10.1016/j.jhep.2013.07.042
9. Huang H, Wu T, Mao J, et al. CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis. *Omics : a journal of integrative biology*. Jun 2015;19(6):339-45. doi:10.1089/omi.2015.0037

## Reimbursement Policy

10. Wang L, Liu T, Zhou J, You H, Jia J. Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy. *Hepatol Res*. Feb 2018;48(3):E283-e290. doi:10.1111/hepr.12982
11. Tendler D. Pathogenesis of nonalcoholic fatty liver disease. Updated August 13, 2024. <https://www.uptodate.com/contents/pathogenesis-of-nonalcoholic-fatty-liver-disease>
12. Abdel-Al A, El-Ahwany E, Zoheiry M, et al. miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients. *Virus research*. Jul 15 2018;253:135-139. doi:10.1016/j.virusres.2018.06.007
13. Fibronostics. LIVERFAst. <https://www.fibronostics.com/liverfast/>
14. CIMA Sciences. OWLiver: Test for Fatty Liver Disease. <https://cimasciences.com/owliver/>
15. BioPredictive. FibroMax. <https://www.biopredictive.com/products/fibromax/>
16. Fouad A, Sabry D, Ahmed R, et al. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study. *Int J Gen Med*. 2013;6:127-34. doi:10.2147/ijgm.s36433
17. Berends MA, Snoek J, de Jong EM, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. *Liver international : official journal of the International Association for the Study of the Liver*. Jun 2007;27(5):639-45. doi:10.1111/j.1478-3231.2007.01489.x
18. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. *Alimentary pharmacology & therapeutics*. Feb 2014;39(3):254-69. doi:10.1111/apt.12569
19. Gao Y, Zheng J, Liang P, et al. Liver Fibrosis with Two-dimensional US Shear-Wave Elastography in Participants with Chronic Hepatitis B: A Prospective Multicenter Study. *Radiology*. Jul 24 2018;172479. doi:10.1148/radiol.2018172479
20. Dong H, Xu C, Zhou W, et al. The combination of 5 serum markers compared to FibroScan to predict significant liver fibrosis in patients with chronic hepatitis B virus. *Clinica chimica acta; international journal of clinical chemistry*. Aug 2018;483:145-150. doi:10.1016/j.cca.2018.04.036
21. Itoh Y, Seko Y, Shima T, et al. The accuracy of noninvasive scoring systems for diagnosing nonalcoholic steatohepatitis-related fibrosis: multi-center validation study. *Hepatol Res*. Jul 4 2018;doi:10.1111/hepr.13226
22. Patel YA, Gifford EJ, Glass LM, et al. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. *Digestive diseases and sciences*. May 19 2018;doi:10.1007/s10620-018-5123-3
23. Kim SS, Nam JS, Cho HJ, et al. Plasma microRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular

## Reimbursement Policy

- carcinoma. *Journal of gastroenterology and hepatology*. Jan 2017;32(1):199-207. doi:10.1111/jgh.13448
24. Suehiro T, Miyaaki H, Kanda Y, et al. Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. *Oncology letters*. Sep 2018;16(3):3267-3273. doi:10.3892/ol.2018.8991
  25. Kar S, Paglialunga S, Jaycox SH, Islam R, Paredes AH. Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis. *PloS one*. 2019;14(7):e0217263. doi:10.1371/journal.pone.0217263
  26. Srivastava A, Jong S, Gola A, et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. *BMC gastroenterology*. Jul 11 2019;19(1):122. doi:10.1186/s12876-019-1039-4
  27. Weis A, Marquart L, Calvopina DA, Genz B, Ramm GA, Skoien R. Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma. *International journal of molecular sciences*. Feb 17 2019;20(4)doi:10.3390/ijms20040864
  28. Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. *Digestive diseases and sciences*. May 2016;61(5):1356-64. doi:10.1007/s10620-016-4079-4
  29. Bril F, McPhaul MJ, Caulfield MP, et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. *J Investig Med*. Feb 2019;67(2):303-311. doi:10.1136/jim-2018-000864
  30. Vali Y, Lee J, Boursier J, et al. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. *J Clin Med*. 2021;10(11):2415. doi:10.3390/jcm10112415
  31. Chow KW, Futela P, Saharan A, Saab S. Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease. *J Clin Exp Hepatol*. Sep-Oct 2023;13(5):783-793. doi:10.1016/j.jceh.2023.01.016
  32. Vali Y, Lee J, Boursier J, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. *Lancet Gastroenterol Hepatol*. Aug 2023;8(8):714-725. doi:10.1016/s2468-1253(23)00017-1
  33. AAFP. Cirrhosis: Diagnosis and Management. *American Family Physician*. 2019. <https://www.aafp.org/pubs/afp/issues/2019/1215/p759.html>
  34. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology (Baltimore, Md)*. Apr 2018;67(4):1560-1599. doi:10.1002/hep.29800
  35. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology (Baltimore, Md)*. Jan 2017;67(1):328-357. doi:10.1002/hep.29367

## Reimbursement Policy

36. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology* (Baltimore, Md). May 1 2023;77(5):1797-1835. doi:10.1097/hep.0000000000000323
37. Sarkar M, Brady CW, Fleckenstein J, et al. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* (Baltimore, Md). Jan 2021;73(1):318-365. doi:10.1002/hep.31559
38. AASLD-IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Updated December 19, 2023.  
[https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA\\_HCVGuidance\\_December\\_19\\_2023.pdf](https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCVGuidance_December_19_2023.pdf)
39. Lim JK, Flamm SL, Singh S, Falck-Ytter YT. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. *Gastroenterology*. May 2017;152(6):1536-1543. doi:10.1053/j.gastro.2017.03.017
40. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. *Gastroenterology*. Oct 2023;165(4):1080-1088. doi:10.1053/j.gastro.2023.06.013
41. WHO. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection.  
[https://apps.who.int/iris/bitstream/handle/10665/154590/9789241549059\\_eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/154590/9789241549059_eng.pdf)
42. WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection <https://iris.who.int/bitstream/handle/10665/376353/9789240090903-eng.pdf>
43. WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection <https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf>
44. USPSTF. Hepatitis C Virus Infection in Adolescents and Adults: Screening. Updated March 2, 2020. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening>
45. NICE. Non-alcoholic fatty liver disease (NAFLD): assessment and management. Updated July 6, 2016.  
<https://www.nice.org.uk/guidance/NG49/chapter/Recommendations#assessment-for-advanced-liver-fibrosis>
46. EASL, EASD, EASO. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *Journal of hepatology*. Jun 2016;64(6):1388-402. doi:10.1016/j.jhep.2015.11.004
47. EASL. EASL recommendations on treatment of hepatitis C: Final update of the series. 2020. <https://easl.eu/wp-content/uploads/2020/10/EASL-recommendations-on-treatment-of-hepatitis-C.pdf>
48. EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. 2017. <https://easl.eu/wp-content/uploads/2018/10/HepB-English-report.pdf>

## Reimbursement Policy

49. EASL, ALEH. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *Journal of hepatology*. Jul 2015;63(1):237-64. doi:10.1016/j.jhep.2015.04.006
50. EASL. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2020 update. 2020. [https://www.echosens.com/wp-content/uploads/2021/07/EASL-CPG-NITs-2021\\_Supplementary-1.pdf](https://www.echosens.com/wp-content/uploads/2021/07/EASL-CPG-NITs-2021_Supplementary-1.pdf)
51. EASL. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *Journal of hepatology*. Sep 2021;75(3):659-689. doi:10.1016/j.jhep.2021.05.025
52. CDC. Clinical Screening and Diagnosis for Hepatitis C. Updated January 31, 2025. <https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing/>

## VI. Revision History

| Revision Date | Summary of Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09/04/2025    | <p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>HBV and HCV allowed tests (all 4) broken out from MASLD, MASH, and AH, revised CC1 now reads: “1) For individuals with a chronic hepatitis B (HBV) or chronic hepatitis C (HCV) viral infection, FibroSURE® (i.e., HBV FibroSURE®, HCV FibroSURE®), ELF™(ELFTM), or FibroTest® testing once every six months MEETS COVERAGE CRITERIA.”</p> <p>Only ELF and FibroTest are appropriate for MASLD, MASH, and AH, these conditions are now found in CC2. Added elevated LSM to rule out cACLD as an appropriate reason for ELF and FibroTest. New CC2 now reads: “2) For individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) (including metabolic dysfunction-associated steatohepatitis [MASH]), or alcoholic hepatitis, or to rule out compensated advanced chronic liver disease (cACLD) for individuals with an elevated liver stiffness measurement, ELF™(ELFTM) or FibroTest® testing once every six months MEETS COVERAGE CRITERIA.”</p> <p>Former CC2, CC3, and CC4, now CC3, CC4, and CC5, edited for clarity, now read: “3) For all situations, including for individuals with any of the conditions described above, the use of other multianalyte assays with algorithmic analysis (e.g., ASH FibroSURE®, LIVERFAST™, NASH FibroSURE®, OWLiver®) DOES NOT MEET COVERAGE CRITERIA.</p> |

## Reimbursement Policy

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>4) For individuals with liver disease not meeting the above criteria, the use of ELFT™(ELFTM), FibroTest®, HBV FibroSURE®, and/or HCV FibroSURE® DOES NOT MEET COVERAGE CRITERIA.</p> <p>5) Except when included as a component of one of the multianalyte assays described above, the use of the following serum biomarkers in the diagnosis, prognosis, or monitoring of chronic liver disease DOES NOT MEET COVERAGE CRITERIA.”</p> <p>Removed CPT code 88341, 88342</p> |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|